Literature DB >> 16234011

Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease.

Peter Ferenci1, Petra Steindl-Munda, Wolfgang Vogel, Wolfgang Jessner, Michael Gschwantler, Rudolf Stauber, Christian Datz, Franz Hackl, Fritz Wrba, Peter Bauer, Oskar Lorenz.   

Abstract

BACKGROUND & AIMS: A 5-fold increase of hepatic copper concentration is considered as the best available test for diagnosis of hepatic Wilson's disease (WD). However, the sensitivity and specificity of this test have never been fully investigated.
METHODS: Copper content was measured by flame atomic absorption spectroscopy in 114 liver biopsies obtained at diagnosis of WD, in 219 patients with noncholestatic liver diseases (including 144 with chronic hepatitis C and 44 with nonalcoholic fatty liver disease), and in 26 without evidence of liver disease.
RESULTS: Liver copper content was >250 microg/g in 95 WD patients (83.3%), between 50 and 250 microg/g in 15, and below 50 microg/g in 4. It did not correlate with age (r(2) = .003), the grade of fibrosis, or the presence of stainable copper. Liver copper content was >250 or between 50 and 250 microg/g in 3 (1.4%) and 20 (9.1%) of 219 patients with noncholestatic liver diseases, respectively. By lowering the cutoff from 250 to 75 microg/g, the sensitivity of liver copper content to diagnose WD increased from 83.3% (95% confidence interval, 75.2%-89.6%) to 96.5% (91.3%-99.1%), but the specificity decreased from 98.6% (96.0%-99.7%) to 95.4% (91.8%-97.8%).
CONCLUSIONS: There is no gold standard for the diagnosis of WD. Liver copper content is a useful parameter, but a value below 250 microg/g does not exclude WD. Diagnosis requires the combination of a variety of clinical and biochemical tests.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16234011     DOI: 10.1016/s1542-3565(05)00181-3

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  35 in total

1.  Liver: A new copper cut-off value for diagnosis of Wilson disease?

Authors:  Wolfgang Stremmel; Uta Merle
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-08-11       Impact factor: 46.802

Review 2.  Update on the Diagnosis and Management of Wilson Disease.

Authors:  Eve A Roberts
Journal:  Curr Gastroenterol Rep       Date:  2018-11-05

Review 3.  Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing.

Authors:  Peter Ferenci
Journal:  Hum Genet       Date:  2006-06-22       Impact factor: 4.132

4.  Hepatocyte GP73 expression in Wilson disease.

Authors:  Lorinda M Wright; Dominik Huster; Svetlana Lutsenko; Fritz Wrba; Peter Ferenci; Claus J Fimmel
Journal:  J Hepatol       Date:  2009-06-25       Impact factor: 25.083

Review 5.  Population screening and diagnostic strategies in screening family members of Wilson's disease patients.

Authors:  Huamei Li; Ran Tao; Lifang Liu; Shiqiang Shang
Journal:  Ann Transl Med       Date:  2019-04

Review 6.  New tools for Wilson's disease diagnosis: exchangeable copper fraction.

Authors:  France Woimant; Nouzha Djebrani-Oussedik; Aurélia Poujois
Journal:  Ann Transl Med       Date:  2019-04

Review 7.  Determination of copper poisoning in Wilson's disease using laser ablation inductively coupled plasma mass spectrometry.

Authors:  Sabine Weiskirchen; Philipp Kim; Ralf Weiskirchen
Journal:  Ann Transl Med       Date:  2019-04

Review 8.  Classification and differential diagnosis of Wilson's disease.

Authors:  Wieland Hermann
Journal:  Ann Transl Med       Date:  2019-04

Review 9.  Wilson disease.

Authors:  Anna Członkowska; Tomasz Litwin; Petr Dusek; Peter Ferenci; Svetlana Lutsenko; Valentina Medici; Janusz K Rybakowski; Karl Heinz Weiss; Michael L Schilsky
Journal:  Nat Rev Dis Primers       Date:  2018-09-06       Impact factor: 52.329

Review 10.  Insights into the management of Wilson's disease.

Authors:  Mohmadshakil Kathawala; Gideon M Hirschfield
Journal:  Therap Adv Gastroenterol       Date:  2017-10-03       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.